Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07669623

Effects of Different Acupuncture Techniques on the Success Rate in Patients With Recurrent Implantation Failure

To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of different acupuncture methods on the success rate in patients with recurrent implantation failure

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Tongji Hospital,Tongji medical college,HUST

Wuhan, Hubei, 430030, China

Location status: Recruiting

Location contact

Cuihong Zheng, professor

CONTACT

[email protected]

86-27-83663275

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meets the criteria for RIF diagnosis (≥ 2 instances of unsuccessful transfer of high-quality embryos).
  • Age: 20 to 40 years old.
  • Planning for a cycle involving the transfer of frozen-thawed embryos (FET).
  • Possession of a transplantable D3 frozen embryo (≥6 cells) or a frozen blastocyst (≥3BC).
  • Estradiol-progesterone replacement therapy: endometrial thickness ≥ 7 mm within the period of endometrial transformation.

Exclusion criteria

  • Individuals planning to undergo preimplantation genetic diagnosis (PGD).
  • Recipients of egg donations.
  • Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms).
  • Patients with known embryo-related factors leading to implantation failure.
  • Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on).
  • Abnormalities in immunity and blood coagulation
  • Recurrent spontaneous abortions (loss of a fetus before 28 weeks of gestation occurring twice or more).
  • Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months.
  • Individuals with untreated hydrosalpinx;
  • Individuals with a Body Mass Index (BMI) below 18 and above 25 kg/ m2.
  • Men with severe abnormalities in semen quality.
  • Individuals with a history of needle phobia.
  • Individuals who have previously participated in this study or received acupuncture treatment within the past three months;
  • Any other conditions deemed unsuitable for participation by the researchers.

Treatment and study plan

Placebo Group

Device

nonpenetrating placebo needles

acupuncture group 1

Device

indwelling intradermal needles

acupuncture group 2

Device

combining fire needle and regular acupuncture

Primary outcomes

  1. clinical pregnancy

    Time frame: 2 years

    defined as ultrasonographic detection of an intrauterine gestational sac following embryo transfer

Secondary outcomes

  1. β-hCG-positive pregnancy

    Time frame: 2 years

    defined as serum β-hCG concentration >10 mIU/mL on day 14 post-transfer

  2. live birth

    Time frame: 3 years

    defined as the delivery of 1 or more living infants at greater than 20 weeks' gestation or birth weight of at least 400 g

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Cui Hong Zheng

Other

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Jun 25, 2026
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.